Akkermansia muciniphila is a mucin-degrading bacterium of the intestinal niche, exerting beneficial effects on the host metabolic profile. Accumulating evidence indicated Akkermansia as a promising therapeutic probiotic against metabolic disorders such as obesity, type 2 diabetes and cardiovascular diseases. However, in specific intestinal microenvironments, its excessive enrichment may be not beneficial. Conditions like inflammatory bowel disease (IBD), Salmonella typhimurium infection or post-antibiotic reconstitution may not benefit from Akkermansia supplementation. Furthermore, using Akkermansia in patients with endocrine and gynecological disorders-such as polycystic ovary syndrome (PCOS) or endometriosis-that have a higher risk of developing IBD, should be critically evaluated. In addition, a cautionary note comes from the neurological field, as the gut microbiota of patients suffering from Parkinson's disease or multiple sclerosis exhibits a characteristic signature of Akkermansia municiphila abundance. Overall, considering these controversial points, the use of Akkermansia should be evaluated on an individual basis, avoiding risking unexpected effects.

Chiantera, V., Laganà, A.S., Basciani, S., Nordio, M., Bizzarri, M. (2023). A Critical Perspective on the Supplementation of Akkermansia muciniphila: Benefits and Harms. LIFE, 13(6) [10.3390/life13061247].

A Critical Perspective on the Supplementation of Akkermansia muciniphila: Benefits and Harms

Chiantera, Vito
Primo
;
Laganà, Antonio Simone;
2023-05-24

Abstract

Akkermansia muciniphila is a mucin-degrading bacterium of the intestinal niche, exerting beneficial effects on the host metabolic profile. Accumulating evidence indicated Akkermansia as a promising therapeutic probiotic against metabolic disorders such as obesity, type 2 diabetes and cardiovascular diseases. However, in specific intestinal microenvironments, its excessive enrichment may be not beneficial. Conditions like inflammatory bowel disease (IBD), Salmonella typhimurium infection or post-antibiotic reconstitution may not benefit from Akkermansia supplementation. Furthermore, using Akkermansia in patients with endocrine and gynecological disorders-such as polycystic ovary syndrome (PCOS) or endometriosis-that have a higher risk of developing IBD, should be critically evaluated. In addition, a cautionary note comes from the neurological field, as the gut microbiota of patients suffering from Parkinson's disease or multiple sclerosis exhibits a characteristic signature of Akkermansia municiphila abundance. Overall, considering these controversial points, the use of Akkermansia should be evaluated on an individual basis, avoiding risking unexpected effects.
24-mag-2023
Settore MED/40 - Ginecologia E Ostetricia
Chiantera, V., Laganà, A.S., Basciani, S., Nordio, M., Bizzarri, M. (2023). A Critical Perspective on the Supplementation of Akkermansia muciniphila: Benefits and Harms. LIFE, 13(6) [10.3390/life13061247].
File in questo prodotto:
File Dimensione Formato  
488 - Akkermansia muciniphila, Benefits and Harms.pdf

accesso aperto

Descrizione: Full text
Tipologia: Versione Editoriale
Dimensione 276.44 kB
Formato Adobe PDF
276.44 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/598613
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 6
social impact